Teniposide for advanced small cell lung cancer with c-Myc
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a chemotherapy drug called teniposide for people with a specific type of advanced small cell lung cancer that has gotten worse after prior treatment. The goal is to see if teniposide helps shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (cancer has spread beyond one lung).
- Your cancer has gotten worse after at least one round of chemotherapy.
- You are in good physical shape (ECOG score 0 or 1, meaning you can do daily activities or light work).
- Your cancer has a specific gene change called 'c-Myc-driven' (your doctor can confirm this).
- You are between 18 and 75 years old.
- You are able to give informed consent (understand and agree to be in the trial).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
This trial compares a treatment plan guided by lab-grown tumor samples (organoids) to standard chemotherapy (topotecan) for people whose extensive-stage small cell lung cancer has come back after initial treatment. It aims to find out which approach works better for your specific cancer.
This trial tests whether a combination of two immunotherapy drugs (toripalimab and JS004) plus chemotherapy can help control relapsed or extensive-stage small cell lung cancer. It is designed for people whose cancer has spread or returned and who are generally healthy enough to receive strong treatment.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.